Peutz-Jeghers Syndrome Clinical Trial
Official title:
Pilot Study of mTOR Inhibitor Therapy for Treatment of Intestinal Polyps in Peutz-Jeghers Syndrome
Pilot study, Open-label, Phase II study of Everolimus.
Objective:
To determine if Everolimus can diminish large gastrointestinal polyps in patients with
Peutz-Jeghers Syndrome.
Methodology:
Polyp size and number will be compared to baseline by FDG-PET and CT and 12 months after
treatment with Everolimus. Since this is a pilot study, the polyps prior to treatment will
serve as the controls.
Peutz-Jeghers Syndrome is a hereditary polyposis condition in which hamartomatous tumors
develop in many tissues of the body. These tumors are benign but frequently cause
gastrointestinal obstruction and bleeding beginning in the 2nd-3rd decades of life
necessitating surgical intervention. Unfortunately, a recent study showed that the lifetime
risk of cancers that arise in Peutz-Jeghers Syndrome is 85% by age 70 years and is 60% by
age 60 years (Hearle et al., 2006).
A working definition of PJS has been suggested by Giardiello et al ,1987(www.genetests.com):
- For individuals with a histopathologically confirmed hamartoma, a definite diagnosis of
PJS requires two of the following three findings:
- Family history consistent with autosomal dominant inheritance
- Mucocutaneous hyperpigmentation (although this can fade with age)
- Small-bowel polyposis
- For individuals without histopathologic verification of hamartomatous polyps, a
probable diagnosis of PJS can be made based on the presence of two of the three
clinical criteria above.
- For individuals without a family history of PJS, diagnosis depends upon the presence of
two or more histologically verified Peutz-Jeghers-type hamartomatous polyps (Tomlinson
& Houlston 1997).
- For individuals with a first-degree relative with PJS, presence of mucocutaneous
hyperpigmentation is sufficient for presumptive diagnosis.
Recently, rapamycin (Rapamune, Wyeth), an FDA-approved drug for use in orthotopic transplant
recipients, was successfully used in an off-label study of 5 individuals with a related
condition called tuberous sclerosis in which the patients had subependymal giant cell
astrocytomas that caused significant and insidious neurological problems such as
hydrocephalus and seizures (Franz, et al. 2006). All astrocytoma lesions exhibited
regression with treatment of oral rapamycin and in one case, necrosis. Treatment was well
tolerated and may offer an alternative to operative therapy in tuberous sclerosis. Tuberous
sclerosis is caused by germline mutations in the tuberous sclerosis 1 or 2 genes. These
genes encode proteins that function downstream of STK11, the gene that is mutated in
Peutz-Jeghers Syndrome. Mutations of STK11 or TSC1/2 leads to activation of mTOR (mammalian
target of rapamycin). Dysregulation of mTOR has been demonstrated in several types of
cancers and clinical trials are underway to see if inhibition of mTOR will be of benefit to
a variety of cancer patients. A recent trial showed efficacy of everolimus in advanced renal
cancer (Hudes, et al. 2007).
All of these studies will be performed on an outpatient basis.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03781050 -
Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers Syndrome
|
Phase 4 | |
Recruiting |
NCT05692596 -
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
|
||
Withdrawn |
NCT01178151 -
Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome
|
Phase 2 | |
Recruiting |
NCT03806075 -
Study of Accurate Diagnosis and Treatment of Peutz-Jeghers Syndrome
|
N/A | |
Recruiting |
NCT06163365 -
Inherited Cancer Early Diagnosis (ICED) Study
|
||
Completed |
NCT06242457 -
Poorly Differentiated Adenocarcinoma of the Jejunum in a Patient With Peutz-Jeghers Syndrome: A Case Report
|
||
Completed |
NCT00438906 -
Cancer of the Pancreas Screening Study (CAPS 3)
|
||
Completed |
NCT00001452 -
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
|
||
Not yet recruiting |
NCT06001476 -
Cold Snare Polypectomy for Small Bowel Polyps in Patients With Peutz-Jeghers Syndrome
|
Phase 4 | |
Recruiting |
NCT04095195 -
Registry of Subjects at Risk of Pancreatic Cancer
|
||
Recruiting |
NCT03050268 -
Familial Investigations of Childhood Cancer Predisposition
|
||
Completed |
NCT00633607 -
Hereditary Colorectal and Associated Tumor Registry Study
|
N/A |